# Correction: Brentuximab vedotin plus chemotherapy for the treatment of front-line systemic anaplastic large cell lymphoma: subgroup analysis of the ECHELON-2 study at 5 years’ follow-up

**Authors:** Eva Domingo-Domènech, Barbara Pro, Tim Illidge, Steven Horwitz, Lorenz Trumper, Swami Iyer, Ranjana Advani, Nancy L. Bartlett, Jacob Haaber Christensen, Won-Seog Kim, Tatyana Feldman, Ilseung Choi, Giuseppe Gritti, David Belada, Andrei Shustov, Arpad Illes, Pier Luigi Zinzani, Andreas Hüttmann, Marek Trneny, Steven Le Gouill, Deepa Jagadeesh, Jonathan W. Friedberg, Meredith Little, Cassie Dong, Michelle Fanale, Keenan Fenton, Kerry J. Savage

PMC · DOI: 10.1038/s41408-025-01432-4 · 2026-01-28

## Full-text entities

- **Genes:** ALK (ALK receptor tyrosine kinase) [NCBI Gene 238] {aka ALK1, CD246, NBLST3}
- **Diseases:** anaplastic large cell lymphoma (MESH:D017728)
- **Chemicals:** CHP (MESH:C048279), Brentuximab vedotin (MESH:D000079963), CHOP (-), A (MESH:D001151)
- **Species:** Homo sapiens (human, species) [taxon 9606]

---
Source: https://tomesphere.com/paper/PMC12852807